openPR Logo
Press release

Investigation announced for Investors in Aptinyx Inc. (NASDAQ: APTX) over possible Violations of Securities Laws

10-08-2019 04:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential securities laws violations by Aptinyx Inc.

An investigation for investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential securities laws violations by Aptinyx Inc.

An investigation was announced over potential securities laws violations by Aptinyx Inc. in connection with certain financial statements.

Investors who purchased shares of Aptinyx Inc. (NASDAQ: APTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Aptinyx Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Evanston, IL based Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx Inc. completed its initial publis offering (“IPO”) on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. However, since the IPO shares of Aptinyx Inc. (NASDAQ: APTX) declined to as low as $2.96 per share on August 26, 2019.

Those who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Aptinyx Inc. (NASDAQ: APTX) over possible Violations of Securities Laws here

News-ID: 1844688 • Views: 245

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of So-Young International Inc. ( …
So-Young International Inc. (NASDAQ: SY) is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of So-Young International Inc. (NASDAQ: SY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of So-Young International Inc. (NASDAQ: SY) concerning whether a
Investigation announced for Long-Term Investors in Cloudera, Inc. (NYSE: CLDR)
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cloudera, Inc. (NYSE: CLDR). Investors who are current long term investors in Cloudera, Inc. (NYSE: CLDR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in Cloudera, Inc. (NYSE: CLDR stocks follows a lawsuit filed
NASDAQ: TSG Investor Notice: Investigation announced over Takeover of The Stars …
An investigation was announced concerning whether the takeover of The Stars Group Inc. is unfair to NASDAQ: TSG stockholders. Investors who purchased shares of The Stars Group Inc. (NASDAQ: TSG) and currently hold any of those NASDAQ: TSG shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of The Stars Group
Deadline on Oct. 14th coming up in Lawsuit filed for certain Investors in CVS He …
A deadline is coming up on October 14, 2019 in the lawsuit filed for certain investors of CVS Health Corporation (NYSE: CVS) over alleged securities laws violations by CVS Health Corporation. Investors who purchased shares of CVS Health Corporation (NYSE: CVS) have certain options and there are strict and short deadlines running. Deadline: October 14, 2019. NYSE: CVS stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Aptinyx

Post-Traumatic Stress Disorder (PTSD) Pipeline Review, H1 2019 by: Actinogen Med …
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2019. Summary: Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy. Report Highlights: Post-Traumatic Stress Disorder (PTSD) market based on elite players, present, past and futuristic data which will offer
Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 |by Trends Anal …
MarketResearchNest.com published an Exclusive Research Report on “Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” that highlights the in-depth market analysis and covers significant data with future prospects of the market. CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle
Chemotherapy Induced Peripheral Neuropathy Treatment Market will reach 1880 mill …
New report published by Global Info Research which offers insights on the global Chemotherapy Induced Peripheral Neuropathy Treatment market. CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
Chemotherapy Induced Peripheral Neuropathy Treatment Market Outlook and Forecast …
The “Global Chemotherapy Induced Peripheral Neuropathy Treatment Analysis to 2025” is a specialized and in-depth study of the Chemotherapy Induced Peripheral Neuropathy Treatment industry with a focus on the global market trend. The report aims to provide an overview of global Chemotherapy Induced Peripheral Neuropathy Treatment with detailed market segmentation by component, type, application and geography. The global Chemotherapy Induced Peripheral Neuropathy Treatment market is expected to witness high growth
Peripheral Neuropathy Treatment Industry 2018: Market Trends, Share, Size, Oppor …
Download PDF Sample @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1749965 The Global Peripheral Neuropathy Treatment Industry Report 2018 is a professional and in-depth study on the current state of the Peripheral Neuropathy Treatment Market. Key Companies Analysis- Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals, TEVA Pharmaceutical Industries, Immune Pharmaceuticals Complete report on Peripheral Neuropathy Treatment market spread across 98 pages, profiling 8 companies and supported with tables
Fibromyalgia Market Key Players – Aptinyx Inc, Daiichi Sankyo Co Ltd, and Inte …
Fibromyalgia Overview Fibromyalgia (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy. Click here for sample report @ https://www.wiseguyreports.com/sample-request/2811443-fibromyalgia-pipeline-review-h1-2018 Top Companies mentioned Aptinyx Inc Astellas Pharma Inc Daiichi Sankyo Co Ltd Innovative Med Concepts LLC Intec Pharma Ltd Jiangsu Hengrui Medicine Co Ltd KPI Therapeutics Inc Merck Fibromyalgia Industry Major Outlook Pharmaceutical and